Irisin vs GLP-1
Head-to-head comparison of Irisin (Irisin (FNDC5 cleavage product)) and GLP-1 (Glucagon-like peptide-1 (7-36 amide)) — benefits, dosing, side effects, research data, and where to buy.
| Property | Irisin | GLP-1 |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Irisin (FNDC5 cleavage product) | Glucagon-like peptide-1 (7-36 amide) |
| Molecular Weight | ~12.3 kDa | 3297 Da |
| Half-Life | hours | 1-2 minutes |
| Amino Acids | 112 | 30 |
| Typical Dose | No approved human dose; research use only | Research-only: 0.1-1.0 pmol/kg/min |
| Route | IV|SC | Intravenous/Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 79 | 1200 |
| Research Status | Pre-clinical | Pre-clinical |
Irisin Benefits
- ✓glucose homeostasis
- ✓energy expenditure
- ✓brown-fat activation
GLP-1 Benefits
- ✓beta-cell protection
- ✓improved insulin secretion
- ✓slower gastric emptying
- ✓lower postprandial glucose
Irisin Dosing
not established|not established
GLP-1 Dosing
0.1-1.0 pmol/kg/min IV infusion in research|0.5-10 nM in vitro|continuous delivery in animal studies
Irisin Side Effects
- ⚠unknown
- ⚠immunogenicity risk
GLP-1 Side Effects
- ⚠nausea at pharmacologic exposure
- ⚠tachyphylaxis with continuous exposure
- ⚠headache
Research Overview
Irisin
Irisin is widely explored in obesity and type 2 diabetes research because it connects exercise biology with metabolic adaptation. Human findings are mixed, so it remains a biomarker and preclinical lead rather than an approved therapy.
GLP-1
Native GLP-1 has a very short half-life because of rapid DPP-4 cleavage, so it is mainly used as a mechanistic research peptide. Across animal and cellular studies it reduces beta-cell apoptosis, improves insulin gene expression, and enhances islet resilience.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.